ID   Mac-2A
AC   CVCL_H637
SY   MAC-2A; MAC2A; McG-2A; PB-2A
DR   cancercelllines; CVCL_H637
DR   Cell_Model_Passport; SIDM01361
DR   Cosmic; 2814457
DR   DepMap; ACH-001119
DR   GEO; GSM2527946
DR   Wikidata; Q54903949
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   PubMed=1532439;
RX   PubMed=2789474;
RX   PubMed=9162223;
RX   PubMed=15356658;
RX   PubMed=28356514;
RX   PubMed=29533902;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Omics: Deep exome analysis.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Donor information: Originally the patient was suffering from Hodgkin lymphoma.
DI   NCIt; C37194; Anaplastic large cell lymphoma, ALK-negative
DI   ORDO; Orphanet_300903; ALK-negative anaplastic large cell lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_H632 ! Mac-2
SX   Male
AG   47Y
CA   Cancer cell line
DT   Created: 11-02-13; Last updated: 05-10-23; Version: 14
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001).
//
RX   PubMed=1532439; DOI=10.1056/NEJM199204233261704;
RA   Davis T.H., Morton C.C., Miller-Cassman R., Balk S.P., Kadin M.E.;
RT   "Hodgkin's disease, lymphomatoid papulosis, and cutaneous T-cell
RT   lymphoma derived from a common T-cell clone.";
RL   N. Engl. J. Med. 326:1115-1122(1992).
//
RX   PubMed=2789474;
RA   Su I.-J., Kadin M.E.;
RT   "Expression of growth factor/receptor genes in postthymic T cell
RT   malignancies.";
RL   Am. J. Pathol. 135:439-445(1989).
//
RX   PubMed=9162223; DOI=10.1006/cyto.1996.0044;
RA   Marti R.M., Wasik M.A., Kadin M.E.;
RT   "Constitutive secretion of GM-CSF by three different cell lines
RT   derived from a single patient with a progressive cutaneous
RT   lymphoproliferative disorder.";
RL   Cytokine 8:323-329(1996).
//
RX   PubMed=15356658; DOI=10.1038/sj.leu.2403465;
RA   Drexler H.G., MacLeod R.A.F.;
RT   "Malignant hematopoietic cell lines: in vitro models for the study of
RT   anaplastic large-cell lymphoma.";
RL   Leukemia 18:1569-1571(2004).
//
RX   PubMed=28356514; DOI=10.1073/pnas.1700682114;
RA   Chen J., Zhang Y., Petrus M.N., Xiao W.-M., Nicolae A., Raffeld M.,
RA   Pittaluga S., Bamford R.N., Nakagawa M., Ouyang S.T.-Y., Epstein A.L.,
RA   Kadin M.E., Del Mistro A., Woessner R.D., Jaffe E.S., Waldmann T.A.;
RT   "Cytokine receptor signaling is required for the survival of ALK-
RT   anaplastic large cell lymphoma, even in the presence of JAK1/STAT3
RT   mutations.";
RL   Proc. Natl. Acad. Sci. U.S.A. 114:3975-3980(2017).
//
RX   PubMed=29533902; DOI=10.1515/hsz-2017-0321;
RA   Drexler H.G., Pommerenke C., Eberth S., Nagel S.;
RT   "Hodgkin lymphoma cell lines: to separate the wheat from the chaff.";
RL   Biol. Chem. 399:511-523(2018).
//